Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this second episode, two pivotal, international publications on Renal Cell Carcinoma from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During the live broadcast on Thursday September 6th 8.30-9.30 PM CEST you have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The expert panel consist of: Prof. John Haanen, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam Hans Westgeest, MD, medical oncologist, Amphia Ziekenhuis, Breda Astrid van der Veldt, MD, PhD, medical oncologist, Erasmus MC, Rotterdam Provisional program: Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma N Engl J Med 378, 2018 IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC) J Clin Oncol 36, 2018 This program is editorially independent and is financially supported by Astellas, BMS, MSD and Roche.